Compare Stocks: ANVS, ALXO, FATE, and ANIK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.03 -2.4%	$2.03	$0.99 ▼ $2.66	$287.62M	0.39	1.15 million shs	603,416 shs
ANIK Anika Therapeutics	$21.00 -2.6%	$18.27	$8.37 ▼ $22.88	$288.40M	0.2	128,728 shs	57,719 shs
ANVS Annovis Bio	$1.37 -19.4%	$1.79	$1.32 ▼ $5.50	$72.43M	1.24	525,033 shs	7.25 million shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-2.40%	-0.98%	+3.05%	+31.82%	+99.02%
ANIK Anika Therapeutics	-2.55%	+0.77%	+7.09%	+45.03%	+133.07%
ANVS Annovis Bio	-19.65%	-24.10%	-26.93%	-27.32%	-40.12%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.03 -2.4%	$2.03	$0.99 ▼ $2.66	$287.62M	0.39	1.15 million shs	603,416 shs
ANIK Anika Therapeutics	$21.00 -2.6%	$18.27	$8.37 ▼ $22.88	$288.40M	0.2	128,728 shs	57,719 shs
ANVS Annovis Bio	$1.37 -19.4%	$1.79	$1.32 ▼ $5.50	$72.43M	1.24	525,033 shs	7.25 million shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-2.40%	-0.98%	+3.05%	+31.82%	+99.02%
ANIK Anika Therapeutics	-2.55%	+0.77%	+7.09%	+45.03%	+133.07%
ANVS Annovis Bio	-19.65%	-24.10%	-26.93%	-27.32%	-40.12%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	126.60% Upside
ANIK Anika Therapeutics	2.75	Moderate Buy	$21.00	N/A
ANVS Annovis Bio	2.25	Hold	$12.00	775.91% Upside
FATE Fate Therapeutics	2.38	Hold	$5.90	143.80% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, FATE, and ANIK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/7/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/30/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $21.00
7/30/2026	ANIK Anika Therapeutics	Barrington Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.98 per share	N/A
ANIK Anika Therapeutics	$112.82M	2.49	N/A	N/A	$10.26 per share	2.05
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.10) per share	N/A
FATE Fate Therapeutics	$6.65M	43.60	N/A	N/A	$1.28 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
ANIK Anika Therapeutics	-$10.88M	-$0.27	N/A	72.41	15.39	-3.14%	0.20%	0.15%	11/4/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)

Latest ANVS, ALXO, FATE, and ANIK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
7/29/2026	Q2 2026	ANIK Anika Therapeutics	$0.03	$0.42	+$0.39	$0.24	$29.21 million	$32.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
ANIK Anika Therapeutics	N/A	4.48	3.19
ANVS Annovis Bio	N/A	3.47	3.47
FATE Fate Therapeutics	N/A	4.85	4.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANIK Anika Therapeutics	91.53%
ANVS Annovis Bio	15.83%
FATE Fate Therapeutics	97.54%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
ANIK Anika Therapeutics	12.08%
ANVS Annovis Bio	20.80%
FATE Fate Therapeutics	4.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
ANIK Anika Therapeutics	300	13.38 million	11.77 million	Optionable
ANVS Annovis Bio	3	42.61 million	33.74 million	Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable

ANVS, ALXO, FATE, and ANIK Headlines

Recent News About These Companies

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

September 3 at 7:00 AM | globenewswire.com

BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE

September 3 at 3:36 AM | marketbeat.com

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

September 2 at 3:25 PM | seekingalpha.com

574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd.

August 30, 2026 | marketbeat.com

487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC

August 27, 2026 | marketbeat.com

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages

August 20, 2026 | marketbeat.com

Fate Therapeutics begins Phase II trial of FT819 for lupus nephritis

August 17, 2026 | yahoo.com

Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE

August 16, 2026 | marketbeat.com

Wedbush Remains a Buy on Fate Therapeutics (FATE)

August 15, 2026 | theglobeandmail.com

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for ...

August 15, 2026 | caledonianrecord.comC

Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE

August 15, 2026 | marketbeat.com

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)

August 14, 2026 | marketbeat.com

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

August 14, 2026 | globenewswire.com

Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

August 13, 2026 | marketbeat.com

Fate Therapeutics, Inc.: Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

August 13, 2026 | finanznachrichten.de

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

August 13, 2026 | zacks.com

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

August 13, 2026 | globenewswire.com

Renaissance Technologies LLC Increases Holdings in Fate Therapeutics, Inc. $FATE

August 8, 2026 | marketbeat.com

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Fate Therapeutics (FATE) Gets a Hold from Needham

July 11, 2026 | theglobeandmail.com

Can Fate Therapeutics (NASDAQ:FATE) Boost Healthcare Stocks?

July 10, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, FATE, and ANIK Company Descriptions

ALX Oncology NASDAQ:ALXO

$2.03 -0.05 (-2.40%)

As of 09/3/2026 04:00 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Anika Therapeutics NASDAQ:ANIK

$21.00 -0.55 (-2.55%)

As of 09/3/2026 04:00 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Annovis Bio NYSE:ANVS

$1.37 -0.33 (-19.41%)

As of 09/3/2026 03:58 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Fate Therapeutics NASDAQ:FATE

$2.42 -0.03 (-1.22%)

As of 09/3/2026 04:00 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, FATE, and ANIK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, FATE, and ANIK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, FATE, and ANIK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, FATE, and ANIK Company Descriptions

ALX Oncology NASDAQ:ALXO

Anika Therapeutics NASDAQ:ANIK

Annovis Bio NYSE:ANVS

Fate Therapeutics NASDAQ:FATE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, FATE, and ANIK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, FATE, and ANIK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, FATE, and ANIK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, FATE, and ANIK Company Descriptions

ALX Oncology NASDAQ:ALXO

Anika Therapeutics NASDAQ:ANIK

Annovis Bio NYSE:ANVS

Fate Therapeutics NASDAQ:FATE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools